Literature DB >> 17118714

A single HBsAg DNA vaccination in combination with electroporation elicits long-term antibody responses in sheep.

Shawn Babiuk1, Cemaine Tsang, Sylvia van Drunen Littel-van den Hurk, Lorne A Babiuk, Philip J Griebel.   

Abstract

Vaccines continue to be the most cost effective method to reduce the burden of disease in both human and animal health. However, there is a need to improve the duration of immunity following vaccination, since maintenance of protective levels of antibody in serum or the ability to rapidly respond upon re-exposure (memory) is critical if vaccines are to provide long-term protective immunity. The purpose of this experiment was to test the duration of antibody responses and the ability to generate anamnestic responses following a single immunization with a DNA vaccine encoding hepatitis B surface antigen (HBsAg) delivered by a variety of routes. Sheep immunized with the conventional HBsAg subunit vaccine (Engerix-B) as well as sheep immunized with a HBsAg DNA vaccine, combined with electroporation, generated significant antibody responses that were sustained for 25 weeks after primary immunization. At 25 weeks, all experimental groups received a secondary immunization with the HBsAg subunit vaccine. Sheep that received a primary DNA immunization, in combination with electroporation, mounted an anamnestic response similar to the cohort immunized with the HBsAg subunit vaccine. In contrast, animals immunized with DNA vaccines administered without electroporation elicited no detectable memory response. The presence of immune memory was significantly correlated with the induction of a prolonged primary immune response. Thus, a single DNA vaccination, in combination with electroporation, approached the efficacy of the commercial subunit vaccine in the maintenance of long-term protective serum antibody titres and immune memory.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118714     DOI: 10.1016/j.bioelechem.2006.10.003

Source DB:  PubMed          Journal:  Bioelectrochemistry        ISSN: 1567-5394            Impact factor:   5.373


  12 in total

1.  DNA vaccine: a promising new approach for chronic hepatitis B therapy.

Authors:  Lucyna Cova
Journal:  Future Virol       Date:  2007-09       Impact factor: 1.831

Review 2.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

3.  Electroporation enhances immunogenicity of a DNA vaccine expressing woodchuck hepatitis virus surface antigen in woodchucks.

Authors:  Katherine H Liu; Mary A Ascenzi; Christine A Bellezza; Abraham J Bezuidenhout; Paul J Cote; Gloria Gonzalez-Aseguinolaza; Drew Hannaman; Alain Luxembourg; Claire F Evans; Bud C Tennant; Stephan Menne
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

4.  Two doses of bovine viral diarrhea virus DNA vaccine delivered by electroporation induce long-term protective immune responses.

Authors:  Sylvia van Drunen Littel-van den Hurk; Zoe Lawman; Marlene Snider; Don Wilson; Jan V van den Hurk; Barry Ellefsen; Drew Hannaman
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

Review 5.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

6.  The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods.

Authors:  Shixia Wang; Chunghua Zhang; Lu Zhang; Jun Li; Zuhu Huang; Shan Lu
Journal:  Vaccine       Date:  2008-03-06       Impact factor: 3.641

7.  Moderate Heat-Assisted Gene Electrotransfer for Cutaneous Delivery of a DNA Vaccine Against Hepatitis B Virus.

Authors:  Chelsea Edelblute; Cathryn Mangiamele; Richard Heller
Journal:  Hum Gene Ther       Date:  2021-06-09       Impact factor: 5.695

8.  Evaluation of a novel non-penetrating electrode for use in DNA vaccination.

Authors:  Amy Donate; Domenico Coppola; Yolmari Cruz; Richard Heller
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

9.  A dendritic cell-targeted chimeric hepatitis B virus immunotherapeutic vaccine induces both cellular and humoral immune responses in vivo.

Authors:  Rajan George; Allan Ma; Bruce Motyka; Yuenian Eric Shi; Qiang Liu; Philip Griebel
Journal:  Hum Vaccin Immunother       Date:  2019-11-26       Impact factor: 3.452

Review 10.  DNA vaccines and their applications in veterinary practice: current perspectives.

Authors:  K Dhama; Mahesh Mahendran; P K Gupta; A Rai
Journal:  Vet Res Commun       Date:  2008-04-19       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.